research use only

Semaglutide GLP-1 Receptor agonist

Cat.No.S9697

Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Jump to

Quality Control

Batch: Purity: 99.95%
99.95

Solubility

In vitro
Batch:

4-Methylpyridine<1 : 4 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 4113.58 Formula Storage (From the date of receipt) 3 years -20°C powder
CAS No. 910463-68-2 -- Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
GLP-1 receptor
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-19)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07772960 NOT_YET_RECRUITING
Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)
Yale University
2026-10-01 PHASE1
NCT06977438 NOT_YET_RECRUITING
Obesity, Childhood
University of Minnesota
2026-10-01 PHASE4
NCT07731256 NOT_YET_RECRUITING
Lower Back Pain; Obesity (BMI>30); Chronic Lower Back Pain; glp1 Agonist
Washington University School of Medicine
2027-02-01 PHASE2
NCT06934655 RECRUITING
Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide
Children's Hospital Los Angeles
2026-09-01 PHASE3
NCT07135245 NOT_YET_RECRUITING
Alzheimer Disease (AD)
Rune Skovgaard Rasmussen
2026-01-01 PHASE2
NCT07090343 NOT_YET_RECRUITING
Aortic Stenosis; Heart Failure
Leiden University Medical Center
2026-04-01 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.